Mural Oncology (NASDAQ:MURA) Earns “Hold” Rating from Jones Trading

Jones Trading reissued their hold rating on shares of Mural Oncology (NASDAQ:MURA) in a research report report published on Tuesday,Benzinga reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Mural Oncology in a report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.00.

Mural Oncology Price Performance

Shares of MURA stock opened at $1.47 on Tuesday. The company has a fifty day moving average price of $3.87 and a two-hundred day moving average price of $3.61. Mural Oncology has a one year low of $1.37 and a one year high of $5.12. The stock has a market cap of $25.33 million, a P/E ratio of -0.16 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period in the previous year, the business earned ($3.57) earnings per share. As a group, equities research analysts anticipate that Mural Oncology will post -7.54 EPS for the current fiscal year.

Institutional Trading of Mural Oncology

Several institutional investors have recently added to or reduced their stakes in MURA. Commerce Bank bought a new position in Mural Oncology during the 3rd quarter worth $39,000. FMR LLC grew its stake in shares of Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after acquiring an additional 11,423 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Mural Oncology in the fourth quarter valued at about $68,000. Two Sigma Advisers LP bought a new position in Mural Oncology during the fourth quarter worth about $84,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Mural Oncology during the 4th quarter worth approximately $94,000. 80.21% of the stock is currently owned by institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.